Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
ZoeNCure Therapeutics secures INR 20 crore ($2.4M) seed funding led by Tyagi Family to advance next-generation ADC program for oncology.
PRIVATESep 03, 2026•4 days ago
Amount Raised
$2.4 Million
Round Type
Seed
BiotechnologyHealth CareTherapeutics
Investors
Manoj TyagiShyambir TyagiTyagi Family
Description
ZoeNCure Therapeutics, an oncology biotechnology company, announced the closing of an INR 20 Crore (approximately $2.4 Million USD) Seed financing round led by the Tyagi Family HNIs. This represents the second investment from the Tyagi Family, bringing total equity raised to INR 22.5 Crore. Proceeds will advance the company's lead ADC candidate toward Phase 1 clinical studies for hepatocellular carcinoma and gastrointestinal cancers, supporting preclinical studies, CMC scale-up, and regulatory submissions to CDSCO.
Company Information
Company
ZoeNCure Therapeutics Pvt. Ltd
About
ZoeNCure Therapeutics is an oncology biotechnology company focused on developing high-potency targeted cancer therapies. The company specializes in next-generation Antibody Drug Conjugate (ADC) programs with dual-payload precision oncology therapies designed to overcome treatment resistance. ZoeNCure is advancing its lead ADC candidate toward Phase 1 clinical studies for severe liver and gastrointestinal cancers, particularly hepatocellular carcinoma (HCC).
Don't miss ZoeNCure Therapeutics Pvt. Ltd's next move
Get an email the moment ZoeNCure Therapeutics Pvt. Ltd raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for ZoeNCure Therapeutics Pvt. Ltd's next move
